SCHEMBL1107225

SCHEMBL1107225

CC(C)(C)OC(=O)NS(=O)(=O)N(Cc1ccc(F)c(C(F)(F)F)c1)c1sc2ccccc2c1Br

nearest known ligand 0.53

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 11/20 0.53
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA7 P43166 1/20 0.34
CA14 Q9ULX7 1/20 0.34
PTGS2 P35354 1/20 0.33
AKT1 P31749 2/20 0.33
P2RX7 Q99572 1/20 0.33
RORC P51449 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13284214 0.91 TRPM8 (0.64) TRPM8CA12CA1CA7CA14
SCHEMBL1107256 0.90 TRPM8 (0.53) TRPM8CA12CA1CA7CA14
SCHEMBL1101011 0.85 TRPM8 (0.55) TRPM8PTGS2P2RX7
SCHEMBL13284216 0.84 TRPM8 (0.56) TRPM8PTGS2P2RX7
SCHEMBL13284218 0.83 TRPM8 (0.54) TRPM8P2RX7
SCHEMBL1107224 0.82 TRPM8 (0.45) TRPM8CA12CA1CA7CA14
SCHEMBL1098507 0.82 TRPM8 (0.57) TRPM8P2RX7
SCHEMBL1099941 0.81 TRPM8 (0.56) TRPM8PTGS2P2RX7
SCHEMBL1098820 0.81 TRPM8 (0.56) TRPM8
SCHEMBL1097972 0.81 TRPM8 (0.56) TRPM8P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-9233947-B2 Sulfamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2016-01-12 US disclosed
US-9233947-B2 Sulfamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2016-01-12 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-20140243329-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-08-28 US disclosed
US-20140243329-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-08-28 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
US-8748478-B2 Sulfamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-06-10 US disclosed
EP-2379521-B1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-01-22 EP disclosed
US-20130237547-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2013-09-12 US disclosed
US-8436041-B2 Sulfamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2013-05-07 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
WO-2010080397-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-07-15 WO disclosed
US-20100160337-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2010-06-24 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237547-A1 SULFAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885CA12 2052/4885CA1 1460/4885
US-20100160337-A1 SULFAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885CA12 2052/4885CA1 1460/4885
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885CA12 2056/4885CA1 1538/4885
US-20140243329-A1 SULFAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885CA12 2052/4885CA1 1460/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885CA12 2056/4885CA1 1538/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885CA12 2056/4885CA1 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.